About Us

At Highland Therapeutics we invest in proprietary drug-delivery technologies to develop improved versions of existing drug products.

What We Do

Highland Therapeutics is the parent company of two wholly owned subsidiaries: Ironshore Pharmaceuticals & Development, Inc. based in the Cayman Islands and Ironshore Pharmaceutics Inc. based in the United States.

Highland Office

Highland Therapeutics Inc.

MaRS Centre, West Tower
661 University Ave, Suite 415
Toronto ON, M5G 1M1


Stephanie Read
Chief Executive Officer

Stephanie Read

Stephanie Read is the Chief Executive Officer of Highland Therapeutics.

In addition to serving as the newly appointed CEO of Ironshore, Stephanie will continue to have a seat on the Highland-Ironshore Board. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I (NASDAQ:ALORU). Ms. Read's 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top and bottom line growth, and diversification of company portfolios. Ms. Read's therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read's industry appointments include the last 6.5 years with CSL (CSL:ASX) as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune (AZN) in a variety of Medical Affairs, Commercial and Business Development roles, and over 6 years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD).

Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.

Nelson Isabel

Nelson Isabel serves as the Vice President, Finance, for Ironshore Pharmaceuticals & Development, Inc.

Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Bausch Health), Canada's largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.